This week, J&J pledged $2 billion to establish a 160,000-square-foot facility at contract manufacturer Fujifilm Biotechnologies’ new biomanufacturing site in North Carolina.
Climate change-driven extreme weather events threaten the pharmaceutical supply chain in the U.S., with 62.8% of facilities in disaster-prone counties, finds new research.
William Blair analysts have initiated coverage of Thermo Fisher and expect the company to build on its status as the “partner of choice” for the biopharma industry.
Outsourced R&D and manufacturing offers substantial cost efficiency, driven by specialized expertise, economies of scale, and access to skilled talent, finds Ind-Ra.
Stockpiling active pharmaceutical ingredients for critical drugs is prudent. However, domestic production of prioritized auxiliary chemicals must be part of strategy.
The Assistant Secretary for Preparedness and Response must come up with a list of approximately 26 drugs, secure a six-month supply, and prioritize domestic sourcing.
The industry’s robotics market showed the strongest sector growth in the second quarter of 2025, according to new data from the Association for Advancing Automation.
While the agency’s PreCheck regulatory framework is a good first step, it remains to be seen whether the program boosts U.S. drug manufacturing, says former FDA official.
The contract manufacturer has 11 late-stage projects with commercial approval potential within the next few years, including a developer of GLP-1 therapeutics for obesity.
President Donald Trump’s playbook is to threaten outrageously high industry-specific tariffs in the hope of pressuring drugmakers to come running back to this country.
The Garden State, called the “medicine chest” to the world, continues to show robust activity with life sciences firms accounting for nearly 30% of all Q2 leasing activity.
President Trump told CNBC his administration would initially levy a “small” pharma-specific tariff, followed by an increase to 150% in a year or so and then as high as 250%.
While the facility has had several run-ins in recent years with U.S. regulators, selling the site is part of Lilly’s broader global manufacturing strategy.
The Bloomington, Indiana facility is a fill-finish site for Regeneron’s Eylea HD and odronextamab and handles the final stages of drug preparation and packaging.
The agreement includes a 15% tariff on branded pharmaceutical products imported from the European Union to the United States, elevating costs across the pharma value chain.
Having an effective strategy so products remain free from contaminants is essential to pharmaceutical manufacturing to prevent delays, product recalls, and patient harm.
The South Korean manufacturer and exporter of biosimilars said it has been designated as the preferred bidder on a large-scale cGMP drug substance facility.
While the drugmaker provided few details on the plan, a new restructuring program is meant to align its global manufacturing to reflect changes in the business.
Although some analysts do not expect it to have a significant financial impact, others project tariffs could increase industry costs by $13 billion to $19 billion per year.
President Donald Trump and European Commission President Ursula von der Leyen appear to differ on how their trade agreement addresses pharma-specific tariffs.
With the looming threat of Trump’s tariffs on pharmaceuticals, major drugmakers continue to invest billions of dollars in domestic manufacturing in the United States.
Marc Casper says the Ridgefield site, which specializes in fill‑finish and packaging of aseptic injectable medications, aligns with its plans to bolster U.S. capacity.
The company saw positive momentum in mammalian, bioconjugates, and small molecules, offsetting lower sales from its cell and gene therapy and microbial businesses.
CEO Pascal Soriot said the company’s capital expenditure will support its goal of reaching $80 billion in revenue by 2030, with 50% generated in the United States.
This week’s announcement about a new multibillion-dollar investment in PCI Pharma Services is good news for contract development and manufacturing organizations.
CEO Joaquin Duato told investors on Wednesday’s earnings call that the provisions of the law have “enabled” Johnson & Johnson’s commitment to invest $55 billion in the U.S.
Peter DeYoung, CEO of Piramal Global Pharma, says the geopolitical situation and trend toward onshoring “happens to be synergistic” with its investment in the United States.
